Dr. Reddy's Laboratories (DRREDDY) — Financial Results

Dr. Reddy's Laboratories reported consolidated revenues of ₹8,545 crores for Q1 FY26, reflecting 11% YoY growth and 26.7% EBITDA margin. Net profit stood at ₹1,418 crores, up 1% YoY with 5% QoQ improvement in PBT. The company highlighted double-digit revenue growth across segments, including a 142% YoY surge in Europe driven by NRT portfolio integration and new launches. Gross margins expanded to 30%, while SG&A declined to 7.3% of revenue. Forward-looking statements noted ongoing USFDA inspections and regulatory observations at three sites, including a 'VAI' designation for the Middleburg facility. The business emphasized sustained momentum in branded markets and emerging regions, supported by volume growth and currency tailwinds.

📄 View Original Announcement (PDF)

📊 Stock Analysis — DRREDDY ✨ Ask AI About This

About Dr. Reddy's Laboratories Limited (DRREDDY)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,11,568.6 Cr P/E: 20.0 ROE: 16.6% ROCE: 19.7%

View full DRREDDY stock details →

📡 Get AI alerts when DRREDDY files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track DRREDDY — Free

💡 Ask AI about this filing

"How does this financial results affect Dr. Reddy's Laboratories Limited's outlook?" "What did Dr. Reddy's Laboratories Limited announce on 23 July 2025?" "Is this positive or negative for DRREDDY?"

Ask AI Free →

📊 More DRREDDY filings

See all DRREDDY filings →

🔥 Also filed on 23 July 2025

BPCL Bharat Petroleum Corporation Limited Corporate Action COLPAL Colgate Palmolive (India) Limited Financial Results SRF SRF Limited Financial Results AXISBANK Axis Bank Limited Financial Results SRF SRF Limited Corporate Action DELHIVERY Delhivery Limited Announcement

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when DRREDDY files new disclosures

Track DRREDDY filings, board meetings, and corporate actions. Free email alerts at 5 PM.